ChrysCapital Acquires 70.68% Stake in Novartis India for ₹1,446 Crore

Private equity firm ChrysCapital has made a significant move in the Indian pharmaceutical sector with the acquisition of a controlling 70.68 per cent stake in Novartis India Limited (NIL), previously held by its parent company, Novartis AG. The acquisition is valued at ₹1,446 crore and marks ChrysCapital’s first majority-controlled investment in the Indian pharmaceutical sector.

ChrysCapital Acquires Controlling Stake in Novartis India

The acquisition was announced after Novartis AG put NIL on the block in 2024, stating that its India-listed entity was under review. NIL will adopt a new name and corporate identity to mark its separation from its previous owners.

The transaction brings a longstanding pharmaceutical business under dedicated private equity ownership, with the ambition to build a leading branded-generics platform for the Indian market.

Key Highlights of the Acquisition

ChrysCapital’s acquisition of NIL marks a significant milestone in the Indian pharmaceutical sector, with the PE firm eyeing growth in the country’s branded generics market.

Market Impact and Details

• NIL operates across therapeutic areas, including pain management, calcium supplementation, gynaecology, neurosciences, and transplant immunology, with brands such as Voveran, Calcium Sandoz, and Tegrital.
• The transaction brings a longstanding pharmaceutical business under dedicated private equity ownership, with the ambition to build a leading branded-generics platform for the Indian market.
• ChrysCapital has appointed a new leadership team, including Dr Vikas Gupta as Chief Executive and Managing Director, and Ramesh Ramadurai, Suchita Sharma, and Shashank Sinha as Independent Directors.

Key Takeaways

• ChrysCapital has acquired a controlling 70.68 per cent stake in Novartis India Limited (NIL) for ₹1,446 crore.
• The acquisition marks ChrysCapital’s first majority-controlled investment in the Indian pharmaceutical sector.
• ChrysCapital has appointed a new leadership team to drive the next phase of growth for NIL.

FAQs

Who acted as the exclusive financial advisor to Novartis AG?

Kotak acted as the exclusive financial advisor to Novartis AG.

Who advised Novartis AG as legal counsel?

Freshfields, AZB & Partners advised Novartis AG as legal counsel.

Who were the financial and tax advisors for ChrysCapital?

Alvarez & Marsal, Dhruva Advisors, and Price Waterhouse & Co. were the financial and tax advisors for ChrysCapital.

Conclusion

The acquisition of Novartis India Limited (NIL) by ChrysCapital marks a significant milestone in the Indian pharmaceutical sector. With a controlling stake in the company, ChrysCapital is well-positioned to drive growth in the country’s branded generics market. As the new leadership team takes the reins, investors and stakeholders can expect significant developments in the coming months. With a strong foundation in place, ChrysCapital is poised to create long-term value for its investors and build a leading branded-generics platform in India.